Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Rating of “Hold” from Brokerages

0

Shares of Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) have been given a consensus rating of “Hold” by the seventeen research companies that currently cover the title, market beat reports. Two research analysts rated the stock with a sell rating, six issued a hold rating and five assigned the company a buy rating. The 12-month average price target among brokerages that updated their coverage on the stock over the past year is $51.63.

FMS has been the subject of a number of research analyst reports. Berenberg Bank cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €84.90 ($89.37) to €83.40 ($87.79) in a Thursday research note March 17. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and reduced its price target for the stock from $32.40 to $30.30 in a Friday, February 11, research note. Oddo Bhf has upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and has set a price target of €72.00 ($75.79) for the company in a research note from Tuesday, March 1. StockNews.com began covering shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday. They set a “buy” rating for the company. Finally, Societe Generale lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a research report from the Friday February 25.

Several hedge funds have recently increased or reduced their holdings in FMS. Pzena Investment Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 47.6% during the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company valued at $307,054,000 after purchasing an additional 3,051,672 shares last quarter. First Trust Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% during the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company valued at $62,496,000 after purchasing an additional 252,768 shares in the last quarter. Cambiar Investors LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 18.3% during the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company valued at $45,935,000 after acquiring an additional 210,819 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Fresenius Medical Care AG & Co. KGaA during the third quarter at a value of $6,977,000. Finally, Invesco Ltd. increased its position in Fresenius Medical Care AG & Co. KGaA by 54.0% during the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company valued at $12,211,000 after acquiring an additional 131,870 shares in the last quarter. 4.73% of the shares are currently held by hedge funds and other institutional investors.

Shares of NYSE FMS opened at $30.16 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 1 year minimum of $28.75 and a 1 year maximum of $42.45. The stock has a market capitalization of $17.67 billion, a P/E ratio of 17.23, a price-to-earnings growth ratio of 1.20 and a beta of 1.17. The company has a 50-day moving average of $32.48 and a 200-day moving average of $32.59. The company has a debt ratio of 0.51, a current ratio of 1.26 and a quick ratio of 0.82.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last released its quarterly earnings data on Tuesday, February 22. The company reported earnings per share of $0.51 for the quarter, beating consensus analyst estimates of $0.50 by $0.01. The company posted revenue of $5.31 billion in the quarter, versus analyst estimates of $5.38 billion. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 4.91% and a return on equity of 6.99%. Research analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 1.99 for the current fiscal year.

The company also recently announced an annual dividend, which will be paid on Friday, May 27. Shareholders of record on Monday, May 16 will receive a dividend of $0.7093. This represents a dividend yield of 3.4%. The ex-dividend date is Friday, May 13. The dividend payout ratio (DPR) of Fresenius Medical Care AG & Co. KGaA is currently 32.57%.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured Articles

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.